Dr. John Charles Tietjen Jr., DO

Dr. Tietjen practices at Albany Medical Center in Albany, New York, part of Albany Med Health System.

Dr. Tietjen's NPI, 1750377420, was assigned on September 27, 2005. Dr. Tietjen graduated from New York College of Osteo Medicine of New York Institute of Technology in 1994. Dr. Tietjen holds New York license 210898-1.

Dr. Tietjen's primary practice is Albany Medical Center, at 43 New Scotland Avenue, Mail Code 34, Albany, NY 12208 in Albany County. The practice phone is (518) 262-2400.

Dr. Tietjen's primary practice is Albany Medical Center in Albany, New York, part of Albany Med Health System. The medical group on file is Albany Med EmUrgentCare. Dmand AI also links Dr. Tietjen to 1 more hospital and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Tietjen practices, 3 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Tietjen's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Tietjen is licensed in New York.

CMS data shows 831 Medicare services from Dr. Tietjen across 6 procedure codes in 2024, for 281 Medicare patients. Medicare paid $59,557 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 281 Medicare patients who saw Dr. Tietjen in 2024. The largest group is 75 to 84, with 92 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 38% are also on Medicaid. Their average risk score is 2.68, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Tietjen's median patient age at 63, with 44% women.

In 2024, Dr. Tietjen wrote 412 Medicare Part D claims for 108 patients. 90% of them were for generic drugs. CMS names the drug for 157 of them, across 8 drugs with 11 or more claims each, at $10,540 in total drug cost. In 2023, CMS named 24 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Tietjen for performance year 2024, reported as part of a group. Dr. Tietjen accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 4 general payments to Dr. Tietjen from 3 drug and device companies from 2017 to 2025. Food and beverage make up the largest share, 90% of the total. Amgen Inc. paid the most, $122.

Dr. Tietjen graduated from New York College of Osteo Medicine of New York Institute of Technology in 1994.